Cargando…

TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer

BACKGROUND: Targeting protein for Xenopus kinesin-like protein 2 (TPX2) overexpression in human tumours is associated with increased malignancy. Its effect on gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC) has not been studied yet. METHODS: The prognostic impact of TPX2 expression...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guenther, Michael, Surendran, Sai Agash, Haas, Michael, Heinemann, Volker, von Bergwelt-Baildon, Michael, Engel, Jutta, Werner, Jens, Boeck, Stefan, Ormanns, Steffen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307892/ https://www.ncbi.nlm.nih.gov/pubmed/37142730 http://dx.doi.org/10.1038/s41416-023-02295-x

Ejemplares similares

Bacterial Lipopolysaccharide as a Negative Predictor of Adjuvant Gemcitabine Efficacy in Pancreatic Cancer
por: Guenther, Michael, et al.
Publicado: (2022)

Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study
por: Guenther, Michael, et al.
Publicado: (2020)

Correction: Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study
por: Guenther, Michael, et al.
Publicado: (2021)

Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel
por: Sams, L., et al.
Publicado: (2021)

Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers
por: Dorman, Klara, et al.
Publicado: (2022)

Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer
por: Mahajan, Ujjwal M, et al.
Publicado: (2019)

Advances in cancer immunotherapy 2019 – latest trends
por: Kruger, Stephan, et al.
Publicado: (2019)

The Impact of SMAD4 Loss on Outcome in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy
por: Ormanns, Steffen, et al.
Publicado: (2017)

Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research
por: Baechmann, Sibylle, et al.
Publicado: (2017)

Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich(LMU) Molecular Tumor Board
por: Dorman, Klara, et al.
Publicado: (2023)

Neoadjuvant chemotherapy in pancreatic cancer: innovative, but still difficult
por: Boeck, S, et al.
Publicado: (2014)

Integrated Analysis of the RASH Study with the Use of the “Burden of Therapy” (BOTh(®TM)) Methodology—A Novel Tool for Assessing Adverse Events in Metastatic Pancreatic Cancer
por: Dorman, Klara, et al.
Publicado: (2023)

Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials
por: Ormanns, Steffen, et al.
Publicado: (2016)

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
por: Heinemann, Volker, et al.
Publicado: (2008)

A Retrospective Analysis of Biliary Tract Cancer Patients Presented to the Molecular Tumor Board at the Comprehensive Cancer Center Munich
por: Zhang, Danmei, et al.
Publicado: (2023)

Ten things the hematologist wants you to know about CAR-T cells
por: Böll, Boris, et al.
Publicado: (2020)

Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective
por: Weiss, L., et al.
Publicado: (2023)

Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer
por: Haas, Michael, et al.
Publicado: (2017)

Systematic comparison of TPX and TPX3 devices regarding luminosity measurements in the ATLAS cavern
por: Fiedler, Petr
Publicado: (2021)

Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study
por: Kruger, S.F., et al.
Publicado: (2022)

pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104
por: Ormanns, Steffen, et al.
Publicado: (2014)

Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer
por: Heinemann, V, et al.
Publicado: (2013)

CCC meets ICU: Redefining the role of critical care of cancer patients
por: von Bergwelt-Baildon, Michael, et al.
Publicado: (2010)

Teaching an old dog new tricks: next-generation CAR T cells
por: Tokarew, Nicholas, et al.
Publicado: (2018)

Unexpected community-acquired co-infections during an ongoing pandemic: (one) too many diagnoses at once
por: Cordas dos Santos, David Manuel, et al.
Publicado: (2021)

Severe hypertension and (renal) thrombotic microangiopathy: solving the puzzle
por: Wehrmann, Florian, et al.
Publicado: (2023)

Study TPX-100-5: intra-articular TPX-100 significantly delays pathological bone shape change and stabilizes cartilage in moderate to severe bilateral knee OA
por: McGuire, Dawn, et al.
Publicado: (2021)

Regulation of Kif15 localization and motility by the C-terminus of TPX2 and microtubule dynamics
por: Mann, Barbara J., et al.
Publicado: (2017)

Treatment, outcome and re-vaccination of patients with SARS-CoV-2 vaccine-associated immune thrombocytopenia
por: Ruzicka, Michael, et al.
Publicado: (2022)

TPX2 is a drag on Eg5
por: Leslie, Mitch
Publicado: (2011)

TPX: Biomedical literature search made easy
por: Joseph, Thomas, et al.
Publicado: (2012)

Enhanced Stability of Li-RHC Embedded in an Adaptive TPX™ Polymer Scaffold
por: Le, Thi Thu, et al.
Publicado: (2020)

Sixth Immunotherapy of Cancer conference (ITOC): advances and perspectives—a meeting report
por: Pinto, Catarina, et al.
Publicado: (2020)

The C-terminal domain of TPX2 is made of alpha-helical tandem repeats
por: Sanchez-Pulido, Luis, et al.
Publicado: (2016)

Projections of cancer incidence and cancer‐related deaths in Germany by 2020 and 2030
por: Quante, Anne S., et al.
Publicado: (2016)

Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report
por: Shimabukuro-Vornhagen, Alexander, et al.
Publicado: (2011)

Structural insight into TPX2-stimulated microtubule assembly
por: Zhang, Rui, et al.
Publicado: (2017)

Prognostic significance of TPX2 and NIBP in esophageal cancer
por: Sui, Chao, et al.
Publicado: (2019)

Molecular mechanism of Aurora A kinase autophosphorylation and its allosteric activation by TPX2
por: Zorba, Adelajda, et al.
Publicado: (2014)

The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cells
por: Shimabukuro-Vornhagen, Alexander, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_aocg2dhcmks7502c5bfffcs9sa